The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multi-institutional retrospective study evaluating clinical outcomes and prognostic factors in patients with metastatic appendiceal adenocarcinoma.
 
Koshiro Fukuda
No Relationships to Disclose
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen - Local PI (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst)
 
Hiroki Osumi
No Relationships to Disclose
 
Takahito Awatsu
No Relationships to Disclose
 
Akira Ooki
Honoraria - Astellas Pharma; Bristol Myers Squibb Foundation; Daiichi Sankyo; Ono Pharmaceutical
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Shota Fukuoka
No Relationships to Disclose
 
Shohei Udagawa
No Relationships to Disclose
 
Takeru Wakatsuki
No Relationships to Disclose
 
Hirokazu Shoji
Consulting or Advisory Role - Astellas Pharma
Research Funding - AbbVie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Elevation Oncology (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Keisho Chin
No Relationships to Disclose
 
Mitsuhiro Fujishiro
No Relationships to Disclose
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kensei Yamaguchi
No Relationships to Disclose
 
Eiji Shinozaki
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Guardant Health; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha